| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 3rd September 2020 | Stephen Richard | 9,310 | Grant/award etc. | $0.00 | |
| 3rd September 2020 | John B Iii Henneman | 9,310 | Grant/award etc. | $0.00 | |
| 6th August 2020 | Richard Hague | 8,545 | Payment by withholding | $1.60 | $13,672.00 |
| 5th August 2020 | John B Iii Henneman | 10,000 | Open or private sale | $15.00 | $150,000.00 |
| 16th July 2020 | Richard Hague | 10,546 | Payment by withholding | $1.52 | $16,029.92 |
| 9th July 2020 | James Loerop | 1,244 | Open or private sale | $35.15 | $43,726.60 |
| 8th July 2020 | James Loerop | 3,000 | Grant/award etc. | $0.00 | |
| 26th June 2020 | Richard Hague | 5,283 | Payment by withholding | $1.37 | $7,237.71 |
| 3rd June 2020 | John B Iii Henneman | 8,488 | Grant/award etc. | $0.00 | |
| 26th May 2020 | Cheryl R Blanchard | 30,000 | Grant/award etc. | $0.00 |
Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company. The company develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.
Ticker: ANIK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 898437
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Goodwill Impairment Loss of $18 M for the period Jan 2020 to Jun 2020 in the context of all up
Fundamentals
Cash at Carrying Value: $117 M (-25%)
Marketable Securities, Current: $28 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $221 M (-5%)
Property, Plant and Equipment, Net: $53 M (3%)
Other Assets, Noncurrent: $13 M (79%)
Assets: $441 M (33%)
Accounts Payable, Current: $6 M (60%)
Liabilities, Current: $28 M (71%)
Other Liabilities, Noncurrent: $843 Th (136%)
Common Stock, Value, Issued: $142 Th (0%)
Common Stock, Shares, Issued: $14 Th (0%)
Additional Paid in Capital, Common Stock: $51 M (3%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $6 M (-1%)
Stockholders' Equity (Parent): $288 M (0%)
Liabilities and Equity: $441 M (33%)
Revenue: $31 M (0%)
Cost of Revenue: $17 M (-45%)
Research and Development: $5 M (-57%)
Operating Income/Loss: $10 M (290%)
Provision for income taxes: $2 M (0%)
EPS (basic): $0.54 (315%)
EPS (diluted): $0.54 (315%)
